Navigation Links
InterMune to Divest Actimmune® (Interferon Gamma-1b)
Date:5/21/2012

f Vidara and InterMune to satisfy the conditions to closing. Other factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 29, 2012 (the "Form 10-K") and quarterly report on Form 10-Q for the three months ended March 31, 2012 filed with the SEC on May 10, 2012 (the "Form 10-Q"), and other periodic reports filed with the SEC, including but not limited to the following: (i) risks related to unexpected regulatory actions or delays or government regulation generally; (ii) risks related to our ability to successfully launch and commercialize Esbriet in the EU, including successfully establishing a commercial operation in the EU and receiving favorable governmental pricing and reimbursement approvals in each EU country; and (iii) InterMune's ability to obtain or maintain patent or other proprietary intellectual property protections.  All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and Form 10-Q and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at www.intermune.com.     

Actimmune® and Esbriet® are registered trademarks of InterMune, Inc.  


'/>"/>
SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... July 28, 2015 On the afternoon of ... company of CPI International, Inc. (CPI), plans to file ... 3, 2015 with the Securities and Exchange Commission and ... the quarter.  At 11 a.m. (EDT) on Wednesday, August ... in conjunction with this release that will be Web ...
(Date:7/28/2015)... A German Diabetes Center clinical study found ... probiotic enriches human gut microbiota and modifies gut production ... involved daily administration of Nutraceutix,s L. reuteri ... BIO- tract ® delivery technology that protects ... way to the intestinal tract. The randomized, ...
(Date:7/28/2015)... July 28, 2015 The Physician-Patient Alliance for ... fundraising campaign, " Surviving Your Hospital Stay ." ... they deserve! None of these patients went home from ... Executive Director, PPAHS) referring to the patient stories ... National Coalition to Promote Continuous Monitoring of Patients on ...
Breaking Medicine Technology:CPI International To Announce Third Quarter 2015 Financial Results 2Nutraceutix's L. reuteri Probiotic Clinically Proven to Modulate Gut Insulin Metabolism 2Surviving Your Hospital Stay: Physician-Patient Alliance for Health & Safety Launches Fundraising for Patient Safety 2
... MATEO, Calif., Feb. 18, 2011 PreXion, Inc., ... 3D Cone Beam Computed Tomography (CBCT) Imaging systems ... and started shipping a new 3D cone beam ... Technology.  The new system incorporates PreXion,s proprietary CLEARimage™ ...
... BARCELONA, Spain, Feb. 18, 2011 Grifols, the Spanish group ... the world,s leading producers of plasma products, will shortly start ... million euros that will employ about 100 people, as soon ... will have the capacity to fractionate 1 million liters of ...
Cached Medicine Technology:PreXion Launches New Faster, Lower Radiation PreXion3D Elite Cone Beam Imaging System 2PreXion Launches New Faster, Lower Radiation PreXion3D Elite Cone Beam Imaging System 3Grifols Starts Construction of a New Plasma Fractionation Plant in Barcelona (Parets Del Valles) 2
(Date:7/28/2015)... ... July 28, 2015 , ... The Triumph Modular, Redefining Modular™ ... education, resource library, floor plans, educational blog and wide use of imagery. The ... posts with valuable links to useful reports by industry experts. Comments are welcomed ...
(Date:7/28/2015)... ... July 28, 2015 , ... World Patent Marketing, a vertically ... invention that makes shelling eggs an exact science. , “The global kitchen appliances ... and Creative Director of World Patent Marketing. “With a growth rate of 6.4%, ...
(Date:7/28/2015)... Chicago, IL (PRWEB) , ... July 28, 2015 ... ... engineer of patented products, announces the Lost and Found, a breakthrough technological ... Bluetooth network. , "Revenue for the consumer electronic industry reached a record high ...
(Date:7/28/2015)... ... 2015 , ... The Denver Foundation and Blair-Caldwell African American ... a photographic and narrative exploration of African American giving, which runs August 1-31 ... Denver is one of only ten cities to host “The Soul of Philanthropy ...
(Date:7/28/2015)... ... ... Morristown Medical Center, part of Atlantic Health System, today announced it was ... the nation, to implant the newly approved CoreValve® Evolut® R System from Medtronic. The ... condition. , The CoreValve® Evolut® R System was approved by the U.S. Food and ...
Breaking Medicine News(10 mins):Health News:Triumph Modular Launches Refreshed Modular Building Industry Website 2Health News:Essential Bang For Your Buck Kitchen Items Presented By World Patent Marketing 2Health News:Essential Bang For Your Buck Kitchen Items Presented By World Patent Marketing 3Health News:Essential Bang For Your Buck Kitchen Items Presented By World Patent Marketing 4Health News:Essential Bang For Your Buck Kitchen Items Presented By World Patent Marketing 5Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 2Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 3Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 4Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 5Health News:"The Soul of Philanthropy Reframed and Exhibited” Comes to Denver 2Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 2Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 3
... PharmaShack.com - ... off on all items, and a new and exciting range of new dietary products such ... ... nowadays, some are planning to go on a diet, others have high cholesterol counts, men ...
... ... the iLASIK procedure is now available in Istanbul Hospitals. Both eyes iLASIK treatment packages ... ... Eye Hospitals is pleased to announce the iLASIK procedure is now available in Istanbul ...
... ... today that Dr. Jon Dishler has been selected by Goldline Research as ... 2009. The list of leading Laser Eye Surgeons of the United States ... leader of numerous FDA laser vision trials, and originator of LASIK in ...
... , NANJING, ... (NYSE: SCR ), a leading pharmaceutical company,specializing in the ... today reported unaudited,financial results for the quarter ended September 30, 2009. ... revenue was RMB443.7 million (US$65.0 million) for the third, ...
... preschool children reports, for the first time, that when ... urine are elevated their sons are less likely to ... and play fighting. The University of Rochester Medical ... of Andrology . Because testosterone produces the masculine ...
... , , SOUTH SAN FRANCISCO, Calif., ... announced that the Company will hold a teleconference and webcast at ... from its pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After ... , Conference Call and Webcast Information ...
Cached Medicine News:Health News:PharmaShack.com Embraces Fall - Offers 15 Percent Off of All Meds on Site 2Health News:iLASIK Treatment Now Available in Istanbul, Turkey at World Eye Hospitals 2Health News:iLASIK Treatment Now Available in Istanbul, Turkey at World Eye Hospitals 3Health News:iLASIK Treatment Now Available in Istanbul, Turkey at World Eye Hospitals 4Health News:Dishler Laser Institute Announces Dr. Jon Dishler Selected as a Leading Laser Eye Surgeon of the United States, as Seen in Forbes Magazine 2Health News:Dishler Laser Institute Announces Dr. Jon Dishler Selected as a Leading Laser Eye Surgeon of the United States, as Seen in Forbes Magazine 3Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 2Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 3Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 4Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 5Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 6Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 7Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 8Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 9Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 10Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 11Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 12Health News:Pilot study relates phthalate exposure to less-masculine play by boys 2Health News:Pilot study relates phthalate exposure to less-masculine play by boys 3Health News:Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer 2
Terumo's Optitorque offers superior torque and precision control. It's patient-friendly, high torque design makes it the catheter of choice for demanding angiography....
Femoral selective catheter. Catheter material used is polyurethane (DUCOR). Guidewire campatibility is 0.038". Packaging 5/Box....
Cordis DUCOR Catheters are available in a broad variety of French sizes and configurations. These catheters combine an atraumatic tip with either a braided or non-braided body....
The advanced center-of-the-arc system allows an infinite choice of trajectories. The system's lightweight durable frame provides accuracy, simplicity, patient mobility and accessibility....
Medicine Products: